Celgene’s (CELG) Revlimid and Pomalyst generated revenues of $2.2 billion and $453 million, respectively in the first quarter compared to $1.9 billion and $364.0 million, respectively, in the first quarter of 2017, reflecting ~18.6% and ~24.5% rises YoY (year-over-year).
Regional revenue trends
In the first quarter, in the US market, Revlimid and Pomalyst generated revenues of $1.5 billion and $300.0 million, respectively, compared to $1.2 billion and $216.0 million in the first quarter of 2017, reflecting rises of ~20.5% and ~38.9%, respectively, YoY.
In the first quarter, in the international market, Revlimid and Pomalyst generated revenues of $747.0 million and $153.0 million, respectively, reflecting rises of ~14.0% and ~3.6%, respectively, YoY.
With increased market penetration by Celgene, in the second quarter, Revlimid and Pomalyst are expected to witness steady sales growth.
Developments in the second quarter
In June, Celgene presented additional results from its Phase 3 RELEVANCE trial, which it conducted in partnership with the Lymphoma Academic Research Organization.
Celgene conducted the Phase 3 RELEVANCE trial to evaluate the safety and efficacy of Revlimid and Rituxan (or a combination therapy) followed by R2 maintenance compared to a traditional Rituxan and chemotherapy combination followed by Rituxan for the treatment of individuals with treatment-naïve follicular lymphoma.
In the clinical trial, a nonchemotherapy treatment regimen showed statistically similar results for the primary endpoints—that is, PFS (progression-free survival) and CR/CRu (complete response or unconfirmed complete response).
Presently, Revlimid and Roche Holding’s (RHHBY) Rituxan combination therapy has not been approved in any country. The success of the clinical trial will aid in the label expansion of Revlimid. The label expansion of Revlimid could significantly boost the drug’s revenue growth.
Some important drugs in the multiple myeloma drug market include Amgen’s (AMGN) Kyprolis, Bristol-Myers Squibb’s (BMY) Empliciti, and Takeda Pharmaceutical’s (TKPYY) Velcade. Kyprolis and Empliciti reported revenues of $222.0 million and $55.0 million, respectively, in the first quarter.
According to the National Cancer Institute estimates, in the United States, 30,770 new incidences of multiple myeloma are expected to be diagnosed, and 12,770 deaths are expected to occur due to multiple myeloma.